



NDA 04-782/S-137

Wyeth Pharmaceuticals Inc.
Attention: James M. Murphy
Associate Director II
Worldwide Regulatory Affairs, CMC
P.O. Box 8299
Philadelphia, PA 19101-8299

Dear Mr. Murphy:

Please refer to your supplemental new drug application dated April 27, 2004, received April 28, 2004, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Premarin® (conjugated estrogens tablets, USP).

We acknowledge receipt of your submissions dated April 28, May 6, June 18 and 22, July 1, 9, 15, 19 and 21, and August 6, 18, 23 and 25, 2004.

This supplemental new drug application provides for reformulation of the Premarin 1.25 mg tablet.

We have completed our review of this application, as amended. This application is approved, effective on date of this letter, for use of Premarin® as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the attached package insert and patient package insert.

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format-NDA (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 04-782/S-137." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kassandra Sherrod, R.Ph., Regulatory Project Manager, at (301) 827-4260.

Sincerely,

{See appended electronic signature page}

Daniel Shames, M.D.
Director
Division of Reproductive and Urologic Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Daniel A. Shames
8/26/04 03:26:28 PM